Documentation

Press release

Datesort descending Press release
12/02/2018 - 17:45 CET Inventiva Full-Year 2017 Financial Information and Business Update
26/02/2018 - 17:45 CET Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients
07/03/2018 - 17:45 CET 2017 Full Year Results: Major progress achieved in clinical development and strong cash position
08/03/2018 - 17:45 CET Inventiva to present at six investor conferences in March 2018
13/03/2018 - 17:45 CET Inventiva’s paper on the discovery and synthesis of its panPPAR agonist lanifibranor accepted and published in the Journal of Medicinal Chemistry of the American Chemical Society
28/03/2018 - 17:45 CET Lanifibranor carcinogenicity studies: Progressing as planned and interim results in rats indicate no compound related urinary bladder tumors
03/04/2018 - 17:45 CET Inventiva Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
16/04/2018 - 12:55 CET Publication of the 2017 registration document (only in French)
02/05/2018 - 18:51 CET Information relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2018 (in french only)
28/05/2018 - 18:04 CET Dr Lucy Lu is appointed to the Inventiva Board of Directors
29/05/2018 - 18:02 CET Résultat des votes de l’Assemblée Générale du 28 mai 2018 (french only)
30/05/2018 - 17:45 CET Inventiva to Present at the Jefferies 2018 Global Healthcare Conference
11/06/2018 - 17:45 CET Inventiva to Present at the 2018 JMP Securities Life Sciences Conference

Pages